foscarnet has been researched along with amphotericin b in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Mitchell, WM; Montefiori, DC; Robinson, WE | 1 |
| Blay, RA; Buck, SM; Epstein, JS; Geyer, S; Mayner, RE; Pollock, L; Selvam, MP | 1 |
| Freifeld, AG | 1 |
| Burney, S; Landman, D; Quale, JM; Zaman, MM | 1 |
| Joannidis, M | 1 |
| Szegedi, J | 1 |
| Sakamoto, M | 1 |
| Bastide, C; Bruyère, F; Chandenier, J; Desoubeaux, G; Fourcade, C; Guy, L; Karsenty, G; Lachaud, L; Lavigne, JP; Malavaud, S; Sotto, A | 1 |
| Didsbury, MS; Kennedy, SE; Mackie, FE | 1 |
7 review(s) available for foscarnet and amphotericin b
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Infectious complications in the immunocompromised host. The antimicrobial armamentarium.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Aminoglycosides; Amphotericin B; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiprotozoal Agents; Azoles; Aztreonam; Cephalosporins; Fluoroquinolones; Foscarnet; Ganciclovir; Humans; Imipenem; Immunocompromised Host; Infections; Neoplasms; Pneumonia, Pneumocystis; Vancomycin | 1993 |
Drug-induced renal failure in the ICU.
Topics: Acute Kidney Injury; Adenine; Amphotericin B; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Calcineurin Inhibitors; Cidofovir; Cyclooxygenase Inhibitors; Cytosine; Foscarnet; Hemodynamics; Humans; Hydroxyethyl Starch Derivatives; Immunoglobulins, Intravenous; Intensive Care Units; Kidney; Organophosphonates; Tacrolimus | 2004 |
[Renal insufficiency caused by medicines, diagnostic processes, toxins].
Topics: Acetaminophen; Acute Kidney Injury; Aminoglycosides; Amphotericin B; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Cisplatin; Contrast Media; Cyclosporine; Foscarnet; Humans; Hungary; Ischemia; Kidney; Kidney Function Tests; Pentamidine; Prognosis | 2007 |
[Adverse effects and safety of antimicrobial agents--nephrotoxicity].
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Antiviral Agents; Foscarnet; Humans; Kidney; Kidney Diseases; Peptides | 2007 |
[Non-antibiotic anti-infectious treatments in urology].
Topics: Acyclovir; Albendazole; Amphotericin B; Anti-Infective Agents; Caspofungin; Cidofovir; Cytosine; Echinocandins; Fluconazole; Flucytosine; Foscarnet; Ganciclovir; Humans; Ivermectin; Lipopeptides; Organophosphonates; Praziquantel; Urologic Diseases; Valganciclovir | 2013 |
A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients.
Topics: Acute Kidney Injury; Adolescent; Amphotericin B; Biomarkers; Child; Cyclosporine; Foscarnet; Glomerular Filtration Rate; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Prognosis; Risk Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
9 other study(ies) available for foscarnet and amphotericin b
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Alkaloids; Amphotericin B; Antiviral Agents; Drug Therapy, Combination; Foscarnet; HIV; Humans; In Vitro Techniques; Indolizines; Interferon beta-1a; Interferon beta-1b; Interferon Type I; Interferon-beta; Interferon-gamma; Interferons; Microbial Sensitivity Tests; Phosphonoacetic Acid; Recombinant Proteins; Ribavirin; RNA, Double-Stranded; Zidovudine | 1989 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine | 1995 |
Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.
Topics: Amphotericin B; Antiviral Agents; Cell Line, Transformed; Cell Survival; Foscarnet; HIV Core Protein p24; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Nystatin; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiviral Agents; Candidiasis; Contraindications; Cytomegalovirus Retinitis; Drug Therapy, Combination; Foscarnet; Humans; Male; Renal Insufficiency | 1996 |